A Phase 3 CHRONOS test from Sanofi and Regeneron Pharmaceuticals of the drug Dupixent shows promise in patients with uncontrolled moderate to severe atopic dermatitis when used with a topical corticosteroid.
Those who took part in the test, which lasted one year, qualified to participate if a topical corticosteroid alone with or without calcineurin inhibitors previously had not managed their atopic dermatitis, according to a press release.
At the 16-week mark of the test, 39 percent of the people who used 300 milligrams of Dupixent with topical solutions weekly or every two weeks could see their skin totally cleared or nearly totally cleared. Twelve percent who used a placebo with topical treatment saw clear skin or almost cleared skin at the same timeframe.
"This study provides positive long-term data for Dupixent, which is important given atopic dermatitis is a chronic inflammatory disease," Dr. Andrew Blauvelt, president of Oregon Medical Research Center and principal investigator of the study, said in the release.
